Answers are grounded in this paper and cite their sources.
Cross-sectional market analysis reviews approval landscapes of follow-on biologics across fifteen countries, highlighting pathways to improve international biosimilar access.
With this study, we try to contribute to discussions on creating more transparency about global approvals of follow-on biologics and promoting access to high-quality biosimilars in countries around the world.
No takes yet. Share an insight, caveat, or question.
Klein et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: